(Almost) everything you learned about pharmacokinetics was (somewhat) wrong!

Anesthesia and Analgesia

Volumn 83, Issue 5, 1996, Pages 901-903

  Fisher, Dennis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANESTHETIC AGENT; ATRACURIUM; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; SUFENTANIL;

DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; EDITORIAL; ERROR; LEARNING; PHARMACOKINETICS; PRIORITY JOURNAL;

ANESTHETICS; ANESTHETICS, INHALATION; ANESTHETICS, INTRAVENOUS; ATRACURIUM; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; NEUROMUSCULAR BLOCKING AGENTS;

EID: 0029974020     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199611000-00002     Document Type: Editorial

References (14)

1. Henthorn TK, Avram MJ, Krejcie TC, et al. Minimal compartmental model of circulatory mixing of indocyanine green. Am J Physiol 1992;262:H903-10.
2. Ducharme J, Varin F, Bevan DR, Donati F. Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters. Clin Pharmacokinet 1993;24:507-18.
3. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992;76:334-41.
4. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 1991;74:53-63.
5. Boyd AH, Eastwood NB, Parker CJ, Hunter JM. Pharmacodynamics of the 1R cis-1'R eis isomer of atracurium (51W89) in health and chronic renal failure. Br J Anaesth 1995;74:400-4.
6. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25:358-71.
7. Kisor DF, Schmith VD, Wargin WA, et al. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996;83:1065-71.
8. Welch RM, Brown A, Ravitch J, Dahl R. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995;58:132-42.
9. Hull CJ. A model for atracurium? [editorial]. Br J Anaesth 1983;5:95-6.
10. Ward S, Neill EAM, Weatherley BC, Corall IM. Pharmacokinetics of atracurium besylate in healthy patients (after a single I.V. bolus dose). Br J Anaesth 1983;55:113-8.
11. Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 1986;65:6-12.
12. Stenlake JB, Waigh RD, Urwin J, et al. Atracurium: conception and inception. Br J Anaesth 1983;55:3S-10S.
13. Ornstein E, Lien CA, Matteo RS, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in geriatric surgical patients. Anesthesiology 1996;84:520-5.
14. De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996;76:624-8.